Figure 1. Proportion of treatment discontinuations and steroid treatment in patients with (a) IAT and (b) ATWB events after ICIs.

ATWB, elevated AT levels along with elevated bilirubin; CTLA-4, cytotoxic T-lymphocyte–associated–protein 4; ICI, immune checkpoint inhibitors; ICI Comb, combination of ICIs; ICI plus antineo, ICI plus antineoplastic treatment; IAT, isolated elevation of AT levels; n, number of events in the treatment group; PD-1, programmed cell death-1; PD-L1, programmed cell death ligand 1.